# Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China

> **NCT06712017** · — · ENROLLING_BY_INVITATION · sponsor: **GrandPharma (China) Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Hepatocellular Carcinoma Non-Resectable

## Interventions

- **DEVICE:** Yttrium-90 (Y-90) resin microspheres

## Key facts

- **NCT ID:** NCT06712017
- **Lead sponsor:** GrandPharma (China) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-08-22
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712017, "Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06712017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*